Gores Holdings X reported a material weakness in internal controls and restated Q3 2025 per-share loss figures after discovering an overstatement in accretion calculations.
The audit committee concluded the Q3 2025 financial statements should no longer be relied upon due to an EPS calculation error (net loss per share restated from $(0.65) to $(0.04)), and management disclosed a material weakness in internal control over financial reporting with disclosure controls deemed ineffective as of September 30, 2026. While the errors had no impact on the balance sheet, net loss or the trust account, non-reliance and control weakness filings typically weigh on sentiment. The restatement actually shows a smaller per-share loss, which limits the downside.
Warrants exercisable at $11.50 per Class A share trade alongside the restatement and material weakness disclosure. The accounting error does not affect the trust account or redemption value, but internal-control weaknesses and non-reliance findings can pressure warrant prices, which are more sensitive to governance and deal-confidence concerns than common shares.
Units (one Class A share plus one-quarter warrant) are exposed to the same governance overhang from the Item 4.02 non-reliance disclosure and the material weakness in internal controls. The underlying accounting error is confined to per-share calculations and does not affect the trust account, tempering the likely price impact.
Gores Holdings X, Inc. announced on November 9, 2026, that its Q3 2025 financial statements should no longer be relied upon due to an error in per-share net loss calculations. The company identified a material weakness in internal controls, leading management to conclude that disclosure controls were ineffective as of September 30, 2026.
No. The company states the errors had no impact on its balance sheets, net income/(loss), cash flows, the trust account or the redemption value of Class A shares; only the per-share calculations were corrected.
Management found a material weakness in internal controls over the per-share calculation and concluded disclosure controls were not effective as of September 30, 2026, which raises governance concerns even though the dollar impact was nil.
The article describes a restatement of per-share figures and a control weakness; it reports no change to the warrant terms, the $11.50 exercise price or the trust account.
The allocation of income among share classes used year-to-date accretion of $31,069,071 instead of the three-month accretion of $3,597,152, overstating accretion by $27,471,919; the Q3 2025 loss per share should have been $(0.04) instead of $(0.65).